FINWIRES · TerminalLIVE
FINWIRES

ASX:TLX

18 stories mentioning ASX:TLX

Every FINWIRES story that references ASX:TLX, newest first.

Asia

Update: Telix Pharmaceuticals, United Imaging Healthcare Sign MOU for US Theranostics Collaboration; Shares Down 3%

(Updates with the stock movement in the headline and last paragraph.)Telix Pharmaceuticals (ASX:TLX) and United Imaging Healthcare North America entered into a memorandum of understanding (MOU) to evaluate a strategic research partnership in the US focused on developing integrated theranostics technologies that combine diagnostics and targeted therapy, Telix said Tuesday after hours.The partnership will evaluate integrating United Imaging's imaging systems, software, connectivity, and artificial intelligence (AI) tools with the company's molecular imaging portfolio and clinical protocols to enhance theranostic workflows.Key focus areas include improving integration of imaging and radiopharmaceutical workflows, standardizing protocol-driven imaging across sites, enhancing treatment planning and patient monitoring, and developing AI-enabled clinical decision support tools.The initial focus will be on TLX101-Px, a positron emission tomography imaging candidate, with opportunities to expand into additional products and markets, as well as pilot programs and protocol optimization efforts.Telix Pharmaceuticals shares fell nearly 3% in recent Wednesday trade.

ASX:TLX
Asia

Telix Pharmaceuticals, United Imaging Healthcare Sign MOU for US Theranostics Collaboration

Telix Pharmaceuticals (ASX:TLX) and United Imaging Healthcare North America entered into a memorandum of understanding (MOU) to evaluate a strategic research partnership in the US focused on developing integrated theranostics technologies that combine diagnostics and targeted therapy, Telix said Tuesday after hours.The partnership will evaluate integrating United Imaging's imaging systems, software, connectivity, and artificial intelligence (AI) tools with the company's molecular imaging portfolio and clinical protocols to enhance theranostic workflows.Key focus areas include improving integration of imaging and radiopharmaceutical workflows, standardizing protocol-driven imaging across sites, enhancing treatment planning and patient monitoring, and developing AI-enabled clinical decision support tools.The initial focus will be on TLX101-Px, a positron emission tomography imaging candidate, with opportunities to expand into additional products and markets, as well as pilot programs and protocol optimization efforts.

ASX:TLX
Asia

Telix Pharmaceuticals Says Prostate Cancer Treatement Candidate Shows Acceptable Tolerability in Phase Three Trial

Telix Pharmaceuticals (ASX:TLX) said its lutetium radio antibody-drug conjugate candidate, TLX591-Tx, demonstrated acceptable tolerability across all standard-of-care combination groups in the ProstACT global phase three study, with no new safety signals, supporting the feasibility of TLX591-Tx in combination with standard-of-care in post-ARPI metastatic castration-resistant prostate cancer, according to a Tuesday statement.The primary endpoint was the safety and tolerability of TLX591-Tx in combination with standard-of-care, while secondary endpoints included pharmacokinetics and radiation dosimetry.The trial enrolled prostate-specific membrane antigen-positive metastatic castration-resistant prostate cancer patients previously treated with one androgen receptor pathway inhibitor. It consisted of TLX591-Tx, administered as two doses 14 days apart, in combination with standard-of-care, which includes abiraterone, enzalutamide, or docetaxel, in comparison with standard-of-care alone. 36 patients received both doses of TLX591-Tx per protocol.Treatment-emergent non-hematologic events were primarily fatigue, nausea, and dry mouth. Radiation exposure to key organs was below established safety limits. Lesion dosimetry confirmed uptake across tumor sites and across all cohorts, while pharmacokinetics demonstrated sustained activity at Day 15.The firm initiated the second part of the study, a randomized treatment expansion, where it obtained regulatory approvals. It is engaging with the US Food and Drug Administration (FDA) to discuss the data from the first part and seek an Investigational New Drug (IND) amendment to advance the second part in the US.

ASX:TLX
Asia

ASX Biggest Losers

Here are the ASX-listed companies with the biggest losses on Tuesday.ASX (ASX:ASX): -12%, AU$51.51Elevra (ASX:ELV): -7%, AU$12.75PEXA Group (ASX:PXA): -7%, AU$10.67Infratil (ASX:IFT): -5%, AU$12.29Yancoal Australia (ASX:YAL): -4%, AU$6.69Telix Pharmaceuticals (ASX:TLX): -4%, AU$12.82Challenger (ASX:CGF): -4%, AU$8.89Whitehaven Coal (ASX:WHC): -4%, AU$8.51Netwealth Group (ASX:NWL): -3%, AU$21.69Paladin Energy (ASX:PDN): -3%, AU$11.13

ASX 200ASX:ASXASX:CGFASX:ELVASX:IFTASX:NWLASX:PDNASX:PXAASX:TLXASX:WHCASX:YAL
Asia

Telix Pharmaceuticals Completes Enrollment in Brain Cancer Drug Trial

Telix Pharmaceuticals (ASX:TLX) has completed patient enrolment in the IPAX-2 study evaluating TLX101-Tx in newly diagnosed glioblastoma, with the company reporting no dose-limiting toxicities observed to date, according to a Tuesday statement.The study is a dose-finding trial evaluating TLX101-Tx in combination with standard post-surgical radiotherapy and temozolomide, and it will proceed with follow-up to establish the maximum tolerated dose.Twelve patients were enrolled in three dose-escalation cohorts across four sites in Australia, Austria, and the Netherlands to assess safety, tolerability, and determine the maximum tolerated dose.TLX101-Tx is also being evaluated in the ongoing pivotal phase three IPAX BrIGHT trial for recurrent glioblastoma, which is currently enrolling patients across multiple countries.

ASX:TLX
Asia

Telix Pharmaceuticals Shares Fall 3% After Entering Collaboration to Explore Prostate Cancer Imaging in New Treatment Approaches

Telix Pharmaceuticals (ASX:TLX) shares fell 3% in recent Monday trade after the company said late Friday it has entered into letters of intent to pursue collaborations with EDAP TMS and Profound Medical, developers of minimally invasive and image-guided ablative treatment technologies for prostate cancer.The company said in a statement that the collaborations will explore the investigational use of its prostate-specific membrane antigen positron emission tomography imaging agents Gozellix and Illuccix with robotic high-intensity focused ultrasound and other image-guided therapies designed to treat localized prostate cancer, including transurethral ultrasound ablation.

ASX:TLX
Asia

Lotus Resources Most Shorted Stock on Australian Bourse, ASIC Data Shows

Lotus Resources (ASX:LOT) was the most shorted stock on the Australian bourse as of May 7, with 16.02% of its total share registry reported as short positions, according to data from the Australian Securities and Investments Commission (ASIC).Domino's Pizza Enterprises (ASX:DMP) was the second most shorted stock, with 15.59% of its share registry reported as short positions. Telix Pharmaceuticals (ASX:TLX) was at the third top spot, with 15.31% of its share registry reported as short positions.The regulator cautioned that its aggregated short position reports are reliant on the accuracy of reports received from individual short sellers.

ASX:DMPASX:LOTASX:TLX
Asia

Telix Pharmaceuticals' Investigational Imaging Agent May Potentially Diagnose a Range of Kidney Cancers

Telix Pharmaceuticals' (ASX:TLX) investigational imaging agent TLX250-Px has the potential to help diagnose kidney cancers beyond just clear cell renal cell carcinoma, or ccRCC, the company said Tuesday, citing an independent analysis published in the European Urology scientific journal.The analysis of phase three trial data showed that positive PET scan findings were "highly predictive" of malignancy overall, including in non-clear cell renal cell carcinoma, with a reported positive predictive value of 98%, the company said."Essentially all false-positives for ccRCC in the ZIRCON study have now been shown to be other malignant kidney cancer subtypes, reducing the risk of overtreatment and further supporting clinical adoption," said Telix Group Chief Medical Officer David Cade.

ASX:TLX
Asia

Telix Says Marketing Authorization Application for Glioma Imaging Candidate Accepted for Review in Europe; Shares Up 3%

Telix Pharmaceuticals (ASX:TLX) said Friday its marketing authorization application filed in Europe for TLX101-Px, its glioma imaging candidate, has been validated and accepted for review, moving into a 210-day active assessment phase.In a statement, the company said it is seeking a broad clinical label, reflective of current clinical practice guidelines, with national marketing authorizations expected to follow shortly after a positive outcome at day 210.The company said it aims to expand patient access to advanced imaging that can distinguish progressive or recurrent glioma from treatment-related changes in both adults and children, with potential for additional future indications.TLX101-Px is also being developed as a patient selection and response assessment tool for Telix's glioblastoma therapy candidate TLX101-Tx, which has been granted orphan drug designation in Europe and the US, per the statement.The phase 3 IPAX-BrIGHT trial of TLX101-Tx in patients with recurrent glioblastoma has started patient dosing internationally and is launching in multiple European countries, the company said.Telix Pharmaceuticals' shares were up 3% in recent Friday trade.

ASX:TLX
Asia

ASX Biggest Losers

Here are the 10 ASX-listed companies with the biggest losses on Monday.Wisetech (ASX:WTC): -3%, AU$42.79NexGen Energy (ASX:NXG): -3%, AU$17.26Telix Pharmaceuticals (ASX:TLX): -2%, AU$14.47Cochlear (ASX:COH): -2%, AU$94.76Paladin Energy (ASX:PDN): -2%, AU$12.28Origin Energy (ASX:ORG): -2%, AU$12.44EVT (ASX:EVT): -2%, AU$12.44Tuas (ASX:TUA): -2%, AU$5.97Ramsay Health Care (ASX:RHC): -2%, AU$39.15Southern Cross Gold (ASX:SX2): -2%, AU$11.07

ASX 200ASX:COHASX:EVTASX:NXGASX:ORGASX:PDNASX:RHCASX:SX2ASX:TLXASX:TUAASX:WTC
Wire

Telix Pharmaceuticals Settles Issue of $600 Million Convertible Notes

Telix Pharmaceuticals (ASX:TLX) said it settled the issue of $600 million in 1.50% convertible notes due 2031, according to a Thursday Australian bourse filing.The convertible notes are expected to be listed on the Official List of the Singapore Exchange Securities Trading on Thursday.In the same filing, the company said that the repurchase of around AU$637 million in principal of the AU$650 million worth of 2.375% convertible bonds due 2029 is "substantially complete."After the repurchase, given that less than 15% in aggregate principal amount of the existing bonds will remain outstanding, Telix said it plans to exercise its right to repurchase and cancel all of the remaining existing bonds at their principal amount.

ASX:TLX
Asia

Telix Pharmaceuticals Becomes Most Shorted ASX Stock as of April 15, ASIC Data Shows

Telix Pharmaceuticals (ASX:TLX) was the most shorted stock on the Australian Securities Exchange as of April 15 with 16.51% short positions, taking the place of Domino's Pizza Enterprises (ASX:DMP), according to data from the Australian Securities & Investments Commission.Domino's Pizza is now the second most shorted stock with 15.44% short positions, data showed.Telix Pharmaceuticals' shares fell 2% in recent Tuesday trade.

ASX:DMPASX:TLX
Asia

Telix Pharmaceuticals Says JPMorgan Increases Stake

Telix Pharmaceuticals (ASX:TLX) said JPMorgan Chase & Co. and its affiliates have increased their stake in the company on Tuesday to 11.5% or 39 million shares from 7.7% or 26.1 million shares, according to a Friday Australian bourse filing.The company's shares fell past 2% in recent Friday trade.

ASX:TLX
Asia

Telix Enters Attractive Market With Late-Stage Brain Cancer Drug Trial in US, Jefferies Says

Telix (ASX:TLX) entered a potentially attractive market after the commencement of phase three trial for recurrent glioblastoma, a type of brain cancer, in the US, Jefferies said in a note on Wednesday.The investment firm said that with around 20,000 patients diagnosed annually in the US with recurrent glioblastoma and limited treatment options, the market appears promising for its drug candidate TLX101-Tx.Jefferies, however, gave a risk-weighted valuation to the experimental drug in Telix's overall valuation.The brokerage boosted Telix's fiscal year 2026 net profit after tax estimate to $5.1 million from $3.3 million, driven by the inclusion of TLX101-Tx in its valuation, with first sales expected in fiscal year 2029, refinancing of $600 million in convertible bonds, and changes to assumptions for expenses and costs.Jefferies kept a buy rating on Telix and raised its price target to AU$27.40 from AU$24.30.

ASX:TLX
Asia

Telix Pharmaceuticals Says First Patient Dosed With Treatment Candidate in Brain Cancer Trial; Shares Fall 6%

Telix Pharmaceuticals (ASX:TLX) said the first patient has been dosed with its treatment candidate TLX101-Tx, or Iodine-131-iodofalan, in its pivotal Ipax BrIGHT trial for recurrent glioblastoma, according to a Wednesday statement from the company.The study is assessing the safety and efficacy of TLX101-Tx in combination with chemotherapy, compared with chemotherapy alone, the company said. It will enroll patients with radiographically confirmed recurrent glioblastoma at first recurrence.The study received regulatory approval in Australia, Austria, Belgium, and the Netherlands, and the firm is seeking approval in more jurisdictions.Telix Pharmaceuticals' shares fell past 6% in recent trading on Wednesday.

ASX:TLX
Asia

Telix Pharmaceuticals Upsizes Convertible Notes Due 2031 to $600 Million

Telix Pharmaceuticals (ASX:TLX) successfully priced and upsized its 1.50% convertible notes due 2031 to $600 million from $550 million, issued through its wholly owned subsidiary, Telix Pharmaceuticals Investments, reflecting strong investor demand, according to a Wednesday Australian bourse filing.The notes can be converted into the company's ordinary shares at an initial conversion price of $13.85, which reflects a premium of around 38% over the reference share price, per the filing.The bonds pay interest quarterly and mature around April 2031, unless they are redeemed or converted earlier, the filing said.The company will simultaneously repurchase and cancel over 85% of its 2029 convertible bonds through a reverse bookbuild process, with settlement for both transactions expected on April 22, the filing added.

ASX:TLX
Asia

Market Chatter: Telix Pharmaceuticals' Pipeline Validated by Regeneron Deal, Citi Says

Telix Pharmaceuticals' (ASX:TLX) co-development deal with US biotech firm Regeneron Pharmaceuticals will likely be perceived as a solid validation of Telix's drug development pipeline, Citi analyst Laura Sutcliffe said, the Australian Financial Review reported Monday.The agreement calls for a $40 million upfront payment and includes four initial programs with options for expansion. It entails a cost and profit-sharing structure, which enables Telix to co-commercialize or opt out in favor of royalties and milestones, AFR reported, citing Citi.Additionally, Regeneron's lack of presence so far in the radiopharmaceuticals field indicates that the deal could open up exposure beyond oncology, possibly expanding the breadth of the tie-up, Sutcliffe reportedly said.Citi kept its buy rating on Telix Pharmaceuticals, according to the report.(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)

ASX:TLX
Asia

Telix Pharmaceuticals, Regeneron Form Radiopharmaceutical Partnership

Telix Pharmaceuticals (ASX:TLX) said it entered into a collaboration with Nasdaq-listed Regeneron Pharmaceuticals to jointly develop and commercialize next-generation radiopharmaceutical therapies, according to a Monday Australian bourse filing.Under the deal, Telix will receive $40 million upfront for four initial programs, the filing said. The collaboration will combine Telix's expertise in radiopharmaceutical development and manufacturing with Regeneron's antibody discovery and oncology experience.Telix said it has the option to co-fund commercialization and profit-share, or earn up to an aggregate of $2.1 billion in development and commercial milestone payments plus low double-digit royalties.Should Telix opt out of the co-funding model for a particular program, it is instead eligible to receive up to $535 million in development and commercial milestones plus low double-digit royalties on future net sales for that program, per the filing.The companies will also jointly develop diagnostic assets, with Telix leading the commercialization and Regeneron receiving a set percentage of profits, the filing said.

ASX:TLX